Nama's AI scorecard currently rates Castle Biosciences, Inc. Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does CSTL report earnings?

Castle Biosciences, Inc.'s next scheduled report is on Nov 2, 2026. Analysts expect EPS of -$0.35.

What is the CSTL price target?

The median analyst price target from 9 analysts is $45.00, with a range of $35.00 – $57.00.

Is CSTL Shariah compliant?

Nama's AAOIFI-style screen reads Castle Biosciences, Inc. as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Castle Biosciences, Inc. (CSTL)

Healthcare · Diagnostics Research · NASDAQ

Castle Biosciences, Inc. (CSTL) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.09B and a free-cash-flow yield of 2.8%. Over the most recent reported fiscal year, revenue grew 3.7% and free cash flow per share fell 21.8%. Nama's AI scorecard rates it Sell, 4.2 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 4.2/10

Negative, at the mild end of Sell — the last band before Hold. As of Oct 4, 2026.

Momentum

Middle · +50.3% over 12 months ex. last

The middle fifth of its market on the past year's move, adjusted for its swings.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-48.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.09B
Trailing P/E	—
Price / book	2.3
Price / sales	3.0
FCF yield	2.8%
Dividend yield	—
Gross margin	77.3%
Operating margin	-9.0%
Net margin	-5.4%
Revenue growth (YoY)	+3.7%
Revenue growth (3-yr annual)	+35.9%
EPS growth (YoY)	-237.1%
FCF/share growth (YoY)	-21.8%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

CSTL earnings

Next report: Nov 2, 2026 (Q3 2026, EPS estimate -$0.35). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Jul 30, 2026	-$0.07	-$0.41	+82.9%	$103.55M
Q1 2026	May 6, 2026	-$0.49	-$0.49	+0.0%	$83.68M
Q4 2025	Feb 26, 2026	-$0.08	-$0.26	+69.2%	$87.01M
Q3 2025	Nov 3, 2025	-$0.02	-$0.51	+96.1%	$83.04M

CSTL analyst price target

Median target $45.00 from 9 analysts, ranging $35.00 – $57.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific Inc.	$242.11B	27.5
DHR	Danaher Corporation	$150.48B	26.4
NTRA	Natera, Inc.	$59.15B	—
A	Agilent Technologies, Inc.	$47.31B	27.7
IQV	IQVIA Holdings Inc.	$42.50B	20.7
WAT	Waters Corporation	$41.75B	31.1
ILMN	Illumina, Inc.	$41.23B	53.0
IDXX	IDEXX Laboratories, Inc.	$40.84B	36.5

Explore live CSTL data on Nama Insights →

CSTL FAQ

Is CSTL a buy?: Nama's AI scorecard currently rates Castle Biosciences, Inc. Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CSTL report earnings?: Castle Biosciences, Inc.'s next scheduled report is on Nov 2, 2026. Analysts expect EPS of -$0.35.
What is the CSTL price target?: The median analyst price target from 9 analysts is $45.00, with a range of $35.00 – $57.00.
Is CSTL Shariah compliant?: Nama's AAOIFI-style screen reads Castle Biosciences, Inc. as Not Shariah Compliant. At least one of the three ratios or the industry test failed.